Umedica Laboratories Private Limited — Ranitidine Exporter Profile
Indian Pharmaceutical Exporter · #10 for Ranitidine · $282.0K export value · DGFT Verified
Umedica Laboratories Private Limited is the #10 Indian exporter of Ranitidine with $282.0K in export value and 23 verified shipments. Umedica Laboratories Private Limited holds a 2.2% market share in Ranitidine exports across 5 countries. The company exports 11 pharmaceutical products worth $32.2M across 8 therapeutic categories.
Umedica Laboratories Private Limited — Ranitidine Export Profile: Buyers & Destinations
Where Does Umedica Laboratories Private Limited Export Ranitidine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| MYANMAR | $134.1K | 12 | 47.5% |
| GAUTEMALA | $113.5K | 4 | 40.3% |
| PHILIPPINES | $27.9K | 5 | 9.9% |
| NEPAL | $3.8K | 1 | 1.3% |
| MOZAMBIQUE | $2.7K | 1 | 1.0% |
Umedica Laboratories Private Limited exports Ranitidine to 5 countries. The largest destination is MYANMAR accounting for 47.5% of Umedica Laboratories Private Limited's Ranitidine shipments, followed by GAUTEMALA (40.3%) and PHILIPPINES (9.9%). These destinations reflect Umedica Laboratories Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ranitidine from Umedica Laboratories Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| PHARMACEUTICAL PRODUCTS LTD | MYANMAR | $134.1K | 12 |
| CORPORACION UMED, S,A, | GAUTEMALA | $113.5K | 4 |
| SUHITAS PHARMACEUTICALS INC | PHILIPPINES | $15.5K | 3 |
| SUHITAS PHARMACEUTICALS INC., | PHILIPPINES | $12.4K | 2 |
| PHARMACARE INTERNATIONAL | NEPAL | $3.8K | 1 |
| AFRI FARMACIA LDA | MOZAMBIQUE | $2.7K | 1 |
Umedica Laboratories Private Limited supplies Ranitidine to 6 buyers globally. The largest buyer is PHARMACEUTICAL PRODUCTS LTD (MYANMAR), followed by CORPORACION UMED, S,A, (GAUTEMALA) and SUHITAS PHARMACEUTICALS INC (PHILIPPINES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ranitidine Export Value and How Much Does Umedica Laboratories Private Limited Contribute?
India exported $8.6M worth of Ranitidine through 1,996 shipments from 248 suppliers to 104 countries, serving 533 buyers globally. Umedica Laboratories Private Limited contributes $282.0K to this total, accounting for 2.2% of India's Ranitidine exports. Umedica Laboratories Private Limited ships Ranitidine to 5 countries through 6 buyers.
What Is the Average Shipment Value for Umedica Laboratories Private Limited's Ranitidine Exports?
Umedica Laboratories Private Limited's average Ranitidine shipment value is $12.3K per consignment, based on 23 shipments totaling $282.0K. The largest destination is MYANMAR (47.5% of Umedica Laboratories Private Limited's Ranitidine exports).
How Does Umedica Laboratories Private Limited Compare to Other Indian Ranitidine Exporters?
Umedica Laboratories Private Limited ranks #10 among 248 Indian Ranitidine exporters with a 2.2% market share. The top 3 exporters are COMBITIC GLOBAL CAPLET PRIVATE LIMITED ($2.7M), EMCURE PHARMACEUTICALS LIMITED ($2.2M), CADILA PHARMACEUTICALS LIMITED ($571.5K). Umedica Laboratories Private Limited processed 23 shipments to 5 destination countries.
What Ranitidine Formulations Does Umedica Laboratories Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| RANITIDINE TABLETS USP 300MG (BOX OF 10X | $113.5K | 4 |
| UMETAC (RANITIDINE INJECTION USP 50MG/2M | $62.0K | 4 |
| UMETAC (RANITIDINE INJECTION USP50MG/2ML) (BOX OF 1X10 AMPOULES) | $29.7K | 2 |
| UMETAC (RANITIDINE INJ USP50MG/2ML) (BOX OF 1X10 AMPOULES) | $29.7K | 2 |
| UMETAC (RANITIDINE INJECTION USP 50MG/2 | $12.8K | 4 |
| AETIN (RANITIDINE INJECTION USP 50MG/2ML) (BOX OF 10 AMPOULES) | $6.2K | 1 |
| MD-CID (RANITIDINE INJECTION USP 50MG/2ML) (BOX OF 10 AMPOULES) | $6.2K | 1 |
| AETIN Ranitidine injection USP 50mg 2ml Pack Size 10X2ML | $6.1K | 1 |
| AETIN (RANITIDINE INJECTION USP 50MG/2M | $4.8K | 1 |
| CONTRACID RANITIDINE INJECTION USP 50MG 2ML BOX OF 10 AMPOULES | $4.6K | 1 |
Umedica Laboratories Private Limited exports 12 distinct Ranitidine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is RANITIDINE TABLETS USP 300MG (BOX OF 10X with 4 shipments worth $113.5K.
How Does Umedica Laboratories Private Limited Compare to Nearest Ranitidine Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | BRAWN LABORATORIES LIMITED | $313.1K | 28 | 4 | $11.2K |
| 7 | ARAVIS PHARMACEUTICALS | $300.0K | 6 | 1 | $50.0K |
| 10 | UMEDICA LABORATORIES PRIVATE LIMITED ★ | $282.0K | 23 | 5 | $12.3K |
| 11 | VKT PHARMA PRIVATE LIMITED | $216.8K | 6 | 1 | $36.1K |
| 12 | AMN LIFE PRIVATE LIMITED | $195.9K | 7 | 1 | $28.0K |
Umedica Laboratories Private Limited ranks #10 among 248 Indian Ranitidine exporters. Average shipment value of $12.3K compared to the market average of $34.8K. The closest competitors by value are BRAWN LABORATORIES LIMITED and ARAVIS PHARMACEUTICALS.
Which Indian Ports Ship Ranitidine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 345 | 17.3% |
| SAHAR AIR | 244 | 12.2% |
| DELHI AIR CARGO ACC (INDEL4) | 231 | 11.6% |
| NHAVA SHEVA SEA (INNSA1) | 155 | 7.8% |
| DELHI AIR | 144 | 7.2% |
| Bombay Air | 79 | 4.0% |
| JNPT | 70 | 3.5% |
| JNPT/ NHAVA SHEVA SEA | 63 | 3.2% |
Geopolitical & Trade Policy Impact on Umedica Laboratories Private Limited's Ranitidine Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Umedica Laboratories. The Israel-Iran conflict has led to disruptions in Middle East trade routes, particularly affecting the Red Sea shipping lanes. Major shipping lines have imposed 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, effectively increasing the cost of exporting goods through these routes. This escalation in shipping costs can erode profit margins and necessitate strategic adjustments in logistics and pricing strategies. (sgeexport.com)
Conversely, the US-China trade tensions have prompted the United States to seek alternative sources for pharmaceuticals, potentially benefiting Indian exporters. However, the imposition of tariffs on Indian goods by the US, including a 25% tariff announced in 2025, poses a significant challenge. This tariff could lead to increased costs for Indian pharmaceutical products in the US market, potentially affecting demand and profitability. (en.wikipedia.org)
The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a promising avenue for Umedica. The FTA eliminates tariffs on Indian pharmaceutical exports to the EU, providing a competitive advantage and facilitating market expansion. This agreement is expected to open a market worth $572.3 billion for Indian pharmaceutical and MedTech exports to Europe from 2027 onward. (mordorintelligence.com)
Umedica Laboratories Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent Good Manufacturing Practice (GMP) requirements. Historically, non-compliance has led to import bans and reputational damage for Indian firms. For instance, in 2013, the FDA banned imports from certain Indian pharmaceutical companies due to GMP violations, highlighting the critical importance of adherence to quality standards. (comcec.org)
While specific regulatory events concerning Umedica Laboratories are not detailed in the available data, the company's sustained export performance suggests a commitment to maintaining high-quality standards and compliance with international regulations. Continuous investment in quality control systems and regulatory compliance is essential to navigate the evolving landscape and to capitalize on global market opportunities.
About Umedica Laboratories Private Limited
Umedica Laboratories Private Limited exports 11 products worth $32.2M. Beyond Ranitidine, top products include Atorvastatin, Calcium, Rosuvastatin, Celecoxib, Hydrocortisone. View the complete Umedica Laboratories Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ranitidine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ranitidine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Umedica Laboratories Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 23 individual customs records matching Umedica Laboratories Private Limited exporting Ranitidine, covering 12 formulations to 5 countries via 6 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 104+ countries, 533+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ranitidine Export Data from Umedica Laboratories Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Umedica Laboratories Private Limited's Ranitidine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Umedica Laboratories Private Limited
Full Company Profile →
11 products · $32.2M total trade · 8 categories
Ranitidine Stats
Company Overview
Top Products by Umedica Laboratories Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Umedica Laboratories Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ranitidine. For current shipment-level data, contact TransData Nexus.